Oramed Pharmaceuticals
ORMP
22 hedge funds and large institutions have $2.73M invested in Oramed Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 9 increasing their positions, 2 reducing their positions, and 3 closing their positions.
350% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 2
103% more capital invested
Capital invested by funds: $1.34M → $2.73M (+$1.38M)
0.72% more ownership
Funds ownership: 1.35% → 2.06% (+0.72%)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
4% less funds holding
Funds holding: 23 → 22 (-1)
71% less call options, than puts
Call options by funds: $9K | Put options by funds: $31K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$499K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$254K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$162K |
| 4 |
Barclays
London,
United Kingdom
|
+$97.1K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$48.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
-$86.2K |
| 2 |
CG
Cutler Group
San Francisco,
California
|
-$38K |
| 3 |
Creative Planning
Overland Park,
Kansas
|
-$16K |
| 4 |
JWA
JFS Wealth Advisors
Hermitage,
Pennsylvania
|
-$4.31K |
| 5 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
-$4K |
ORMP Hedge Fund Activity: Q3 2017 in Review
22 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q3 2017, worth a combined $2.73M — up 103% from $1.34M a quarter earlier.
Fund positioning in ORMP was balanced in Q3 2017: 3 funds opened new positions, 3 closed out, 9 added to existing stakes and 2 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $499K. The largest seller was Glenmede Trust, cutting an estimated $86.2K.
- 22 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q3 2017, down from 23 in Q2 2017.
- Funds reported $2.73M of Oramed Pharmaceuticals stock for Q3 2017, up 103% quarter-over-quarter.
- 3 funds opened new Oramed Pharmaceuticals positions in Q3 2017 and 3 closed out, a net change of 0 holders.
- The largest Oramed Pharmaceuticals buyer in Q3 2017 was Renaissance Technologies, an estimated $499K added.
- The largest Oramed Pharmaceuticals seller in Q3 2017 was Glenmede Trust, an estimated $86.2K sold.
Based on aggregated 13F filings for Q3 2017.